1GAAP net loss of $2.7M for FY2025, representing a 224.7% year-over-year decline driven by lower PBRT and Gamma Knife procedure volumes.
2Net cash provided by operating activities increased to $3.1M in FY2025, up from $167k in FY2024, supporting near-term operating needs.
3Capital expenditures totaled $7.6M in FY2025, slightly down from $7.9M in FY2024, focused on high-priority medical equipment upgrades.
4FY2025 free cash flow was negative $4.5M, as capital investment outpaced operating cash generation during the period.
5Lower direct patient service Gamma Knife volumes resulted from planned downtime for a Peru facility upgrade and relocation.
6LINAC procedure volumes rose in FY2025, driven by the 2024 RI Acquisition and launch of the new Puebla, Mexico treatment facility.
7Near-term liquidity risk has increased following Fifth Third’s notification of an event of default under the company’s credit agreements.